An introduction to exercise metabolism 1
46 min
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Introduction
-
16 min
1. Psychopharmacology: structural aspects of the brain- Prof. Brian Leonard
-
66 min
2. The nature of chemical neurotransmission- Prof. Brian Leonard
-
28 min
3. Psychotropic drugs- Prof. Brian Leonard
-
26 min
4. Psychopharmacology of anxiety disorders- Prof. Brian Leonard
-
35 min
5. Psychopharmacology of depression- Prof. Brian Leonard
-
48 min
6. Psychopharmacology of mania and schizophrenia- Prof. Brian Leonard
-
45 min
7. The role of stress and immune system in psychiatric disorders- Prof. Brian Leonard
- Introduction to Genetic Investigations of Complex Traits
-
39 min
- Genetics and Pharmacokinetics of Psychotropic Drugs
-
34 min
9. Genetics of phase I enzymes- Prof. Aiming Yu
-
36 min
10. Phase II metabolism- Prof. Ann Daly
- Genetics and Pharmacodynamics of Psychotropic Drugs
-
25 min
-
25 min
-
52 min
13. Genetic polymorphisms influencing the response of antidepressants- Prof. Alessandro Serretti
- Clinical Applications of Psychopharmacogenetics
-
41 min
14. Of genes and drugs: genetic determinants of adverse drug reactions- Dr. Mario Masellis
-
35 min
15. Cocaine and amphetamine addiction genetics- Dr. Gerome Breen
-
29 min
- Archived Lectures *These may not cover the latest advances in the field
-
47 min
-
37 min
18. Genetic determinants of metabolism: clinical applications in psychiatry- Prof. Julia Stingl (formerly Kirchheiner)
-
36 min
-
47 min
20. Genetic polymorphisms influencing response to lithium- Prof. Alessandro Serretti
-
28 min
21. Genetic determinants of antipsychotic-induced weight gain- Prof. Gavin Reynolds
-
59 min
-
50 min
-
37 min
24. Genetic determinants of agranulocytosis- Dr. Michael Dettling
Printable Handouts
Navigable Slide Index
- Introduction
- Outline
- Inter-patient variations in drug therapy
- Variations in phase I metabolism
- Causes of inter-patient variations
- Phase I drug-metabolizing enzymes
- Genetics of human CYP enzymes
- Genetic polymorphism of CYP enzymes
- Clinically important human phase I CYP isozymes
- CYP2C19 pharmacogenetics
- Psychotropic drugs metabolized by CYP2D6
- Human CYP2D gene cluster
- CYP2D6 genetic variants
- Debrisoquine and CYP2D6 genetic polymorphism
- Nortriptyline: an excellent example
- Fluoxetine N-demethylation by CYP2D6 isoforms
- CYP2D6 polymorphism: inter-ethnic difference
- Debrisoquine phenotype: inter-ethnic difference
- CYP2D6 polymorphism and drug inactivation
- CYP2D6 polymorphism and prodrug activation
- Metabolism of codeine
- Morphine production in CYP2D6 EMs and PMs
- Pain tolerance in CYP2D6 EMs and PMs
- Codeine intoxication associated with CYP2D6 UM
- CYP2D6 is expressed in human brain
- CYP genetic polymorphism: issues
- CYP genetic polymorphism: opportunity
- Phenotyping towards individualized drug therapy
- Genotyping towards individualized drug therapy
- CYP2D6 genotyping towards individualized therapy
- Genotyping/phenotyping methods: comparison
- Phenotyping vs. genotyping: pros and cons
- Potency of CYP2D6 inhibitor
- Drug-drug interactions altered CYP2D6 activity
- CYP2D6 polymorphism: psychopharmacotherapy
- References
Topics Covered
- Inter-patient variations caused by Phase I drug metabolizing enzymes
- Genetic polymorphism of CYP2D6 and impact on psychopharmacotherapy
- Metabolism, pharmacokinetics, pharmacodynamics and toxicity
- Pharmacogenetics and pharmacogenomics move towards individualized drug therapy
Links
Series:
Categories:
Talk Citation
Yu, A. (2007, October 1). Genetics of phase I enzymes [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved August 31, 2024, from https://doi.org/10.69645/HEZV1564.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Aiming Yu has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Genetics of phase I enzymes
Published on October 1, 2007
34 min
